CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. T ...

Company Overview - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs [3] - The company has proprietary platforms for cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADCs, leading to a pipeline of product candidates [3] Pipeline and Product Candidates - Mersana's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2) [3] Upcoming Financial Updates - Mersana Therapeutics will provide business updates and report its financial results for the second quarter ended June 30, 2025, on August 13, 2025 [1] - A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day [1]